New research uncovers key factors driving survival and treatment response in patients with HER2-positive breast cancer ...

The combination of toripalimab, nimotuzumab, and chemotherapy showed “promising antitumor activity with acceptable toxicity,” researchers wrote.

近日,中山大学肿瘤医院泌尿外科韩辉教授团队在Cancer Cell(影响因子48.8)发表了题为Neoadjuvant toripalimab plus nimotuzumab combined with taxol-based ...

Recent investigation focuses on the effects of BRCA1 and BRCA2 tumor pathogenic variants (tPVs) within the parameters of two ...

Dr. Matthew Galsky discusses the FDA approval of Imfinzi and chemo before and after surgery for muscle-invasive bladder ...

For patients with breast cancer, the brain functional network shows a shift toward a more randomized pattern after neoadjuvant chemotherapy (NAC), with progression of chemotherapy leading to expanded ...

Surgery may not be the best next course of treatment for p atients with early-stage breast cancer who had a complete response to neoadjuvant (pre-surgical) chemotherapy and standard radiation ...

Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented Initiation of Phase 3 trial sites underway for pivotal study of IMNN-001 ...